<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Oral Cancer News &#187; carboplatin</title>
	<atom:link href="http://oralcancernews.org/wp/tag/carboplatin/feed/" rel="self" type="application/rss+xml" />
	<link>http://oralcancernews.org/wp</link>
	<description>The Oral Cancer Foundation News Archive</description>
	<lastBuildDate>Mon, 06 Feb 2012 22:09:34 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>Neck response to chemoradiotherapy</title>
		<link>http://oralcancernews.org/wp/neck-response-to-chemoradiotherapy/</link>
		<comments>http://oralcancernews.org/wp/neck-response-to-chemoradiotherapy/#comments</comments>
		<pubDate>Wed, 18 Nov 2009 02:34:20 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[carboplatin]]></category>
		<category><![CDATA[chemoradiotherapy]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[CT imaging]]></category>
		<category><![CDATA[lymph nodes]]></category>
		<category><![CDATA[neck dissection]]></category>
		<category><![CDATA[paclitaxel]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=7385</guid>
		<description><![CDATA[Source: Arch Otolaryngol Head Neck Surg. 2009;135(11):1133-1136 Author: Alexander Langerman, MD et al. Complete Radiographic Response Correlates With Pathologic Complete Response in Locoregionally Advanced Head and Neck Cancer Objective: The role of neck dissection following chemoradiotherapy (CRT) for locoregionally advanced head and neck cancer is an area of active debate. Patients who have a complete [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/neck-response-to-chemoradiotherapy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Oncolytics&#8217; Phase III borrows adaptive design in SPA trial</title>
		<link>http://oralcancernews.org/wp/oncolytics-phase-iii-borrows-adaptive-design-in-spa-trial/</link>
		<comments>http://oralcancernews.org/wp/oncolytics-phase-iii-borrows-adaptive-design-in-spa-trial/#comments</comments>
		<pubDate>Mon, 05 Oct 2009 11:59:16 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[carboplatin]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[oncolytic virus]]></category>
		<category><![CDATA[Oncolytics Biotech]]></category>
		<category><![CDATA[paclitaxel]]></category>
		<category><![CDATA[Reolysin]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=6787</guid>
		<description><![CDATA[Source: www.bioworld.com Author: Catherine Hollingsworth Oncolytics Biotech Inc. reached agreement with the FDA on the design of a Phase III trial of Reolysin in head and neck cancer, marking the first such agreement for an intravenously administered oncolytic virus. The Phase III trial will be conducted in two stages and will cost an estimated $15 [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/oncolytics-phase-iii-borrows-adaptive-design-in-spa-trial/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Oncolytics Biotech(R) Inc. collaborators present positive head and neck results in phase I/II combination</title>
		<link>http://oralcancernews.org/wp/oncolytics-biotechr-inc-collaborators-present-positive-head-and-neck-results-in-phase-iii-combination/</link>
		<comments>http://oralcancernews.org/wp/oncolytics-biotechr-inc-collaborators-present-positive-head-and-neck-results-in-phase-iii-combination/#comments</comments>
		<pubDate>Mon, 23 Mar 2009 13:53:05 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[carboplatin]]></category>
		<category><![CDATA[paclitaxel]]></category>
		<category><![CDATA[platinum treatment]]></category>
		<category><![CDATA[Reolysin]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=1787</guid>
		<description><![CDATA[Source: pr-canada.net Author: press release Oncolytics Biotech Inc. announced that interim clinical results from its Phase I/II U.K. trial of Reolysin(R) combined with paclitaxel/carboplatin for patients with advanced cancers were presented at the Fifth International Meeting on Replicating Oncolytic Virus Therapeutics. The meeting is being held in Banff, Alberta from March 18th to 22nd, 2009. [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/oncolytics-biotechr-inc-collaborators-present-positive-head-and-neck-results-in-phase-iii-combination/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New platinum-phosphate compounds kill ovarian vancer cells, other cancer cells</title>
		<link>http://oralcancernews.org/wp/new-platinum-phosphate-compounds-kill-ovarian-vancer-cells-other-cancer-cells/</link>
		<comments>http://oralcancernews.org/wp/new-platinum-phosphate-compounds-kill-ovarian-vancer-cells-other-cancer-cells/#comments</comments>
		<pubDate>Sat, 22 Nov 2008 15:00:49 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[carboplatin]]></category>
		<category><![CDATA[cisplatin]]></category>
		<category><![CDATA[phosphaplatins]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=762</guid>
		<description><![CDATA[Source: www.sciencedaily.com Author: staff A new class of compounds called phosphaplatins can effectively kill ovarian, testicular, head and neck cancer cells with potentially less toxicity than conventional drugs, according to a new study published in the journal Proceedings of the National Academy of Sciences. The compounds could be less harmful than current cancer treatments on [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/new-platinum-phosphate-compounds-kill-ovarian-vancer-cells-other-cancer-cells/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Virus accomplice helps drugs fight cancer</title>
		<link>http://oralcancernews.org/wp/virus-accomplice-helps-drugs-fight-cancer/</link>
		<comments>http://oralcancernews.org/wp/virus-accomplice-helps-drugs-fight-cancer/#comments</comments>
		<pubDate>Fri, 07 Nov 2008 21:05:54 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[carboplatin]]></category>
		<category><![CDATA[docetaxel]]></category>
		<category><![CDATA[paclitaxel]]></category>
		<category><![CDATA[Reolysin]]></category>
		<category><![CDATA[reovirus]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=667</guid>
		<description><![CDATA[Source: www.newscientist.com Author: Andy Coghlan A virus that harmlessly infects most people at some time in their lives appears to help anti-cancer drugs destroy tumours, or at least keep them in check. Known as a reovirus, it destroys tumour cells because they lack the cellular machinery that keeps the virus in check in healthy cells. [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/virus-accomplice-helps-drugs-fight-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Oncolytics reports positive results from phase I/II cancer studies</title>
		<link>http://oralcancernews.org/wp/oncolytics-reports-positive-results-from-phase-iii-cancer-studies/</link>
		<comments>http://oralcancernews.org/wp/oncolytics-reports-positive-results-from-phase-iii-cancer-studies/#comments</comments>
		<pubDate>Tue, 04 Nov 2008 20:29:01 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[carboplatin]]></category>
		<category><![CDATA[paclitaxel]]></category>
		<category><![CDATA[platinum/taxane]]></category>
		<category><![CDATA[Reolysin]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=653</guid>
		<description><![CDATA[Source: www.pharmaceutical-business-review.com Author: staff Oncolytics Biotech has announced positive interim results in its Phase I and Phase II UK combination Reolysin and paclitaxel/carboplatin clinical trials for patients with advanced cancers. Four of the responding patients continue on study, while a fifth patient is too early to evaluate for response, the company said. These results appear [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/oncolytics-reports-positive-results-from-phase-iii-cancer-studies/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Oncolytics Biotech Inc. starts patient enrolment in U.S. phase 2 clinical trial investigating Reolysin(R) in combination with paclitaxel and carboplatin</title>
		<link>http://oralcancernews.org/wp/oncolytics-biotech-inc-starts-patient-enrolment-in-us-phase-2-clinical-trial-investigating-reolysinr-in-combination-with-paclitaxel-and-carboplatin/</link>
		<comments>http://oralcancernews.org/wp/oncolytics-biotech-inc-starts-patient-enrolment-in-us-phase-2-clinical-trial-investigating-reolysinr-in-combination-with-paclitaxel-and-carboplatin/#comments</comments>
		<pubDate>Fri, 12 Sep 2008 19:44:22 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[carboplatin]]></category>
		<category><![CDATA[oncolytic viruses]]></category>
		<category><![CDATA[paclitaxel]]></category>
		<category><![CDATA[Reolysin(R)]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=351</guid>
		<description><![CDATA[Source: www.marketwatch.com Author: press release Oncolytics Biotech Inc. announced today that that it has started patient enrollment in a Phase 2 clinical trial using intravenous administration of Reolysin(R) in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers. The Principal Investigator is Dr. Monica Mita of the Cancer Therapy &#038; Research [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/oncolytics-biotech-inc-starts-patient-enrolment-in-us-phase-2-clinical-trial-investigating-reolysinr-in-combination-with-paclitaxel-and-carboplatin/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Platinum-based chemotherapy plus cetuximab in head and neck cancer</title>
		<link>http://oralcancernews.org/wp/platinum-based-chemotherapy-plus-cetuximab-in-head-and-neck-cancer/</link>
		<comments>http://oralcancernews.org/wp/platinum-based-chemotherapy-plus-cetuximab-in-head-and-neck-cancer/#comments</comments>
		<pubDate>Thu, 11 Sep 2008 15:55:37 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[carboplatin]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[cisplatin]]></category>
		<category><![CDATA[metastatic squamous-cell carcinoma]]></category>
		<category><![CDATA[platinum-based chemotherapy]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=348</guid>
		<description><![CDATA[Source: New England Journal of Medicine, Volume 359:1116-1127, September 11, 2008, Number 11 Authors: Jan B. Vermorken, M.D., Ph.D. et al. Background: Cetuximab is effective in platinum-resistant recurrent or metastatic squamous-cell carcinoma of the head and neck. We investigated the efficacy of cetuximab plus platinum-based chemotherapy as first-line treatment in patients with recurrent or metastatic [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/platinum-based-chemotherapy-plus-cetuximab-in-head-and-neck-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

